Abbott completes acquisition of Exact Sciences

ABBOTT PARK, Ill. — Abbott has finalized its acquisition of Exact Sciences, strengthening its position in the rapidly growing cancer screening and diagnostics market and significantly expanding its reach in early detection and precision oncology.

The deal makes Exact Sciences a wholly owned subsidiary of Abbott, with March 20 being the last day for trading Exact Sciences shares on the Nasdaq. Financial terms were not disclosed.

Abbott chairman and chief executive officer Robert B. Ford said the combination enhances the company’s ability to scale access to critical diagnostic tools globally. “Abbott’s global scale, track record of operational and commercial excellence and work with healthcare systems around the world will expand access to important tools for early cancer detection and personalized treatments,” Ford said. “With the legacy and deep expertise of the Exact Sciences team, we’re ready to transform cancer care.”

The acquisition enables Abbott to speed up the development of diagnostics that are more preventative, predictive, and personalized, while establishing a leadership position in the estimated $60 billion U.S. cancer screening and precision diagnostics market.

Through the transaction, Abbott expands its portfolio of widely used cancer detection and monitoring tools, including the Cologuard noninvasive colorectal cancer screening test, Oncotype DX for guiding treatment decisions in early-stage breast cancer, and emerging solutions such as Oncodetect for molecular residual disease detection and Cancerguard, a multi-cancer early detection blood test.

The combined company will also utilize a pipeline of next-generation diagnostics designed to detect cancer earlier, improve treatment pathways, and support ongoing disease monitoring.

Abbott said the acquisition supports its broader strategy to drive growth in high-impact healthcare segments while advancing its mission to improve access and give patients greater control over their health.